Amgen Inc (AMGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ
Market Cap: $251.89B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amgen Inc (AMGN) Earnings: Report Dates and Results
Amgen (AMGN) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Amgen reported EPS of $6.45, above the $5.74 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AMGN has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 8.1% above the $5.29 reported for the quarter ended Dec 31, 2025.
AMGN Earnings Call
The latest AMGN earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, AMGN beat 36, missed 3 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $10.37B, up 8.5% from $9.56B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $6.45 | $5.74 | $5.47 - $6.09 | +12.37% | Beat | +14.4% | 29 | 2 up, 3 down | Nov 3, 2026 | $10.37B |
| Jun 30, 2026 | $6.29 | $5.60 | $4.99 - $6.28 | +12.32% | Beat | +4.5% | 28 | 5 up, 5 down | Aug 4, 2026 | $10.05B |
| Mar 31, 2026 | $5.15 | $4.77 | $4.17 - $5.24 | +7.97% | Beat | +5.1% | 29 | 10 up, 7 down | Apr 30, 2026 | $8.62B |
| Dec 31, 2025 | $5.29 | $4.73 | $4.05 - $5.74 | +11.84% | Beat | -0.4% | 23 | 8 up, 3 down | Feb 3, 2026 | $9.87B |
| Sep 30, 2025 | $5.64 | $5.01 | $4.38 - $5.42 | +12.57% | Beat | +1.1% | 26 | 8 up, 5 down | Nov 4, 2025 | $9.56B |
| Jun 30, 2025 | $6.02 | $5.28 | $4.81 - $5.84 | +14.02% | Beat | +21.1% | 27 | 13 up, 2 down | Aug 5, 2025 | $9.18B |
| Mar 31, 2025 | $4.90 | $4.26 | $3.89 - $5.11 | +15.02% | Beat | +23.7% | 24 | 6 up, 5 down | May 1, 2025 | $8.15B |
| Dec 31, 2024 | $5.31 | $5.08 | $4.71 - $5.79 | +4.53% | Beat | +12.7% | 22 | 7 up, 4 down | Feb 4, 2025 | $9.09B |
| Sep 30, 2024 | $5.58 | $5.11 | $4.91 - $5.42 | +9.20% | Beat | +12.5% | 21 | 5 up, 1 down | Oct 30, 2024 | $8.50B |
| Jun 30, 2024 | $4.97 | $5.00 | $4.80 - $5.43 | -0.60% | Miss | -0.6% | 21 | 11 up, 0 down | Aug 6, 2024 | $8.39B |
| Mar 31, 2024 | $3.96 | $3.89 | $3.32 - $4.87 | +1.80% | Beat | -0.5% | 21 | 5 up, 0 down | May 2, 2024 | $7.45B |
| Dec 31, 2023 | $4.71 | $4.59 | $4.33 - $5.09 | +2.61% | Beat | +15.2% | 20 | 4 up, 0 down | Feb 6, 2024 | $8.20B |
| Sep 30, 2023 | $4.96 | $4.68 | N/A | +5.98% | Beat | +5.5% | 19 | 5 up, 3 down | Oct 31, 2023 | $6.90B |
| Jun 30, 2023 | $5.00 | $4.49 | $3.92 - $4.84 | +11.36% | Beat | +7.5% | 20 | 7 up, 3 down | Aug 3, 2023 | $6.99B |
| Mar 31, 2023 | $3.98 | $3.85 | $3.30 - $4.49 | +3.38% | Beat | -6.4% | 20 | 1 up, 2 down | Apr 27, 2023 | $6.11B |
| Dec 31, 2022 | $4.09 | $4.09 | $3.94 - $4.25 | 0.00% | In line | -6.2% | 20 | 3 up, 1 down | Jan 31, 2023 | $6.84B |
| Sep 30, 2022 | $4.70 | $4.45 | $4.23 - $4.75 | +5.62% | Beat | +0.6% | 21 | 8 up, 4 down | Nov 3, 2022 | $6.65B |
| Jun 30, 2022 | $4.65 | $4.33 | $3.95 - $4.87 | +7.39% | Beat | +6.2% | 21 | 9 up, 1 down | Aug 4, 2022 | $6.59B |
| Mar 31, 2022 | $4.25 | $4.12 | $3.70 - $4.55 | +3.16% | Beat | +14.9% | 18 | 4 up, 3 down | Apr 27, 2022 | $6.24B |
| Dec 31, 2021 | $4.36 | $4.04 | $3.66 - $5.08 | +7.92% | Beat | +14.4% | 21 | 4 up, 1 down | Feb 7, 2022 | $6.85B |
| Sep 30, 2021 | $4.67 | $4.22 | $3.95 - $4.92 | +10.66% | Beat | +6.9% | 20 | N/A | Nov 2, 2021 | $6.71B |
| Jun 30, 2021 | $4.38 | $4.01 | $3.83 - $4.49 | +9.23% | Beat | +3.1% | 21 | N/A | Aug 3, 2021 | $6.53B |
| Mar 31, 2021 | $3.70 | $4.04 | $3.68 - $4.41 | -8.42% | Miss | -11.3% | 21 | N/A | Apr 27, 2021 | $5.90B |
| Dec 31, 2020 | $3.81 | $3.35 | $3.09 - $4.07 | +13.73% | Beat | +4.7% | 25 | N/A | Feb 2, 2021 | $6.63B |
| Sep 30, 2020 | $4.37 | $3.75 | $3.47 - $4.16 | +16.53% | Beat | +19.4% | 24 | N/A | Oct 28, 2020 | $6.42B |
| Jun 30, 2020 | $4.25 | $3.77 | $3.10 - $4.31 | +12.73% | Beat | +7.1% | 23 | N/A | Jul 28, 2020 | $6.21B |
| Mar 31, 2020 | $4.17 | $3.75 | $3.19 - $4.09 | +11.20% | Beat | +17.1% | 21 | N/A | Apr 30, 2020 | $6.16B |
| Dec 31, 2019 | $3.64 | $3.42 | $3.07 - $3.83 | +6.43% | Beat | +6.4% | 18 | N/A | Jan 30, 2020 | $6.20B |
| Sep 30, 2019 | $3.66 | $3.53 | $3.17 - $3.72 | +3.68% | Beat | -0.8% | 21 | N/A | Oct 29, 2019 | $5.74B |
| Jun 30, 2019 | $3.97 | $3.58 | $3.33 - $3.78 | +10.89% | Beat | +3.7% | 19 | N/A | Jul 30, 2019 | $5.87B |
| Mar 31, 2019 | $3.56 | $3.48 | $3.04 - $3.76 | +2.30% | Beat | +2.6% | 19 | N/A | Apr 30, 2019 | $5.56B |
| Dec 31, 2018 | $3.42 | $3.27 | $3.16 - $3.42 | +4.59% | Beat | +18.3% | 18 | N/A | Jan 29, 2019 | $6.23B |
| Sep 30, 2018 | $3.69 | $3.45 | $3.12 - $3.71 | +6.96% | Beat | +12.8% | 18 | N/A | Oct 30, 2018 | $5.90B |
| Jun 30, 2018 | $3.83 | $3.56 | $3.10 - $3.67 | +7.58% | Beat | +17.1% | 18 | N/A | Jul 26, 2018 | $6.06B |
| Mar 31, 2018 | $3.47 | $3.25 | $2.97 - $3.50 | +6.77% | Beat | +10.2% | 18 | N/A | Apr 24, 2018 | $5.55B |
| Dec 31, 2017 | $2.89 | $3.03 | $2.90 - $3.23 | -4.62% | Miss | 0.0% | 19 | N/A | Feb 1, 2018 | $5.80B |
| Sep 30, 2017 | $3.27 | $3.10 | $2.87 - $3.24 | +5.48% | Beat | +8.3% | 20 | N/A | Oct 25, 2017 | $5.77B |
| Jun 30, 2017 | $3.27 | $3.11 | $2.99 - $3.22 | +5.14% | Beat | +15.1% | 20 | N/A | Jul 25, 2017 | $5.81B |
| Mar 31, 2017 | $3.15 | $3.01 | N/A | +4.65% | Beat | +8.6% | N/A | N/A | Apr 26, 2017 | $5.46B |
| Dec 31, 2016 | $2.89 | $2.79 | N/A | +3.58% | Beat | +10.7% | N/A | N/A | Feb 2, 2017 | $5.96B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $21.85, up 10.2% from the year before. It was $11.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $21.85 | +10.2% |
| Dec 31, 2024 | $19.82 | +6.3% |
| Dec 31, 2023 | $18.65 | +5.4% |
| Dec 31, 2022 | $17.69 | +3.4% |
| Dec 31, 2021 | $17.11 | +3.1% |
| Dec 31, 2020 | $16.60 | +11.9% |
| Dec 31, 2019 | $14.83 | +2.9% |
| Dec 31, 2018 | $14.41 | +14.5% |
| Dec 31, 2017 | $12.58 | +8.0% |
| Dec 31, 2016 | $11.65 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,358 | 18 | |
| 2026Q2 | Jun 30, 2026 | 8,285 | 18 | |
| 2026Q1 | Mar 31, 2026 | 8,946 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,838 | 17 | |
| 2025Q3 | Sep 30, 2025 | 9,083 | 16 | |
| 2025Q2 | Jun 30, 2025 | 7,922 | 22 | |
| 2025Q1 | Mar 31, 2025 | 6,316 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,578 | 21 |
2026Q3 Earnings Call
Opening remarks
Casey Capparelli Vice President of Investor Relations Thank you, Julianne. Good afternoon, everyone, and welcome to our third quarter of 2026 earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Murdo Gordon, Jay Bradner, and Thomas Dittrich. Through the course of our discussion today, we will use non-GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward-looking statements, which are qualified by our safe harbor statement. Please note that actual results can vary materially. Over to you, Bob.
Robert Bradway CEO Good afternoon, and thank you for joining our call. Our results through the first 3 quarters of the year reflect the strength of our business across a broad range of products and pipeline molecules. This is exactly the kind of performance our strategy was designed to achieve. Strong commercial and operations execution and continued innovation from our research and development organization reinforce our confidence in Amgen's ability to deliver durable long-term growth. For the latest quarter, total revenues grew a strong 8% year-over-year to $10.4 billion. Our 6 key growth drivers grew 27% year-over-year and represented over 70% of our third quarter product sales. Across the portfolio, 17 products delivered double-digit sales growth and 17 products are now annualizing at more than $1 billion based on third quarter sales. We see significant opportunity to build on this momentum. Many of our medicines address large, underpenetrated disease areas where the majority of patients remain untreated. Repatha, EVENITY, and TEZSPIRE are clear examples of that. Our strong financial performance gives us the flexibility to invest in innovation and the capabilities needed to support future growth while delivering attractive returns to shareholders. In the third quarter, we generated $3.7 billion in free cash flow, increased our investment in research and development by 11% year-over-year, and invested another $600 million in the business through capital expenditures. This was another productive quarter for our R&D organization. We reported positive Phase III results from 3 important programs: IMDELLTRA, in small cell lung cancer, where we are working to establish it as the cornerstone therapy; TEZSPIRE, in eosinophilic esophagitis, an area with significant unmet need; and dazodalibep, in Sjogren's disease, where no approved disease-modifying therapies currently exist. I would note that each of these represents an established or potential first-in-class medicine with the opportunity to make a meaningful difference for patients while providing additional sources of long-term growth for Amgen. Likewise, our progress reflects the strength of our science and our commitment to pursuing novel approaches for serious diseases. That same focus guides our investment in programs such as MariTide, which is advancing through Phase III development.
Frequently Asked Questions About AMGN
When is Amgen's next earnings date?
Amgen's next earnings report is expected for Feb 1, 2027.
Did AMGN beat earnings estimates last quarter?
Yes. Amgen reported EPS of $6.45 for the quarter ended Sep 30, 2026, above the $5.74 estimate, a 12.37% surprise.
What EPS do analysts expect from AMGN next quarter?
The consensus EPS estimate for Amgen for the quarter ending Dec 31, 2026 is $5.72 from 30 analysts, with estimates from $5.03 to $6.38.
How often does AMGN beat earnings estimates?
Amgen beat the EPS estimate in each of the last 9 quarters, with an average surprise of +11.09%.
AMGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts